Sun Pharma’s arm to raise up to Rs 1,000 crore to fund internal restructuring

14 Dec 2015 Evaluate

Sun Pharmaceutical Industries’ subsidiary Sun Laboratories is planning to hit the domestic bond market in order to raise up to Rs 1,000 crore to fund an internal restructuring. The Mumbai-based drug maker has divided the issue into two parts of Rs 500 crore, one maturing in two years and the other in three years. It is priced in the range of 7.90%-7.96%, 25-35 basis points higher than similar maturity government securities, making the borrowing cost less than any term bank loan.

Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. The company provides high quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide.


Sun Pharma Inds. Share Price

1669.20 -31.35 (-1.84%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×